|

Atezolizumab Clinical Trials

102 actively recruiting trials across 43 locations

▼ -2 trials since August 2026

Also known as: 1380723-44-3, Atezolizumab (Tecentriq, ATEZOLIZUMAB), Immunoglobulin G1, Anti-CD274 mAb (MPDL3280A), RG7446, RO5541267, Alectinib, Atezolizumab combined with bevacizumab, Ceritinib, Dostarlimab +23 more

Pipeline

Phase 1: 15Phase 2: 42Phase 3: 13Phase 4: 3Phase 1/2: 21Phase 2/3: 4

Top Sponsors

  • National Cancer Institute (NCI)6
  • Hoffmann-La Roche5
  • M.D. Anderson Cancer Center4
  • Emory University3
  • Vanderbilt-Ingram Cancer Center2

Indications

Other31 trials

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Phase 2
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Phase 1
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Phase 3
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Phase 2
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
Phase 2
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
Phase 2
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
Phase 2
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Phase 2/3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Phase 2/3
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Phase 4
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Phase 2
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Phase 3
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Phase 2
Improving Public Cancer Care by Implementing Precision Medicine in Norway
Phase 2
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Phase 1/2
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
Phase 2
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
Phase 1
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Phase 2
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer
Phase 2
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
Phase 2
Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Phase 2
Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)
Phase 2
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Phase 2
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Phase 3
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Phase 3
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Phase 2

Duarte, California8 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

City of Hope

Phase 1/2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope - Duarte

Phase 1/2
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

City of Hope Comprehensive Cancer Center

Phase 2
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

City of Hope

Phase 1
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

City of Hope /ID# 261468

Phase 2/3
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Local Institution - 0137

Phase 1/2
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

Birmingham, Alabama4 trials

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

UAB Comprehensive Cancer Center

Phase 1
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

University of Alabama -Birmingham

Phase 1/2
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The Kirklin Clinic of University of Alabama Birmingham Hospital

Phase 1/2
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

University of Alabama at Birmingham

Phase 1/2

Atlanta, Georgia4 trials

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

Chilldren's Healthcare of Atlanta

Phase 1
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Emory University Hospital Midtown

Phase 2
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Winship Cancer Institute at Emory University

Phase 2
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

Emory University Hospital Midtown

Phase 2

Houston, Texas4 trials

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Houston Methodist Research Institute

Phase 4
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M D Anderson Cancer Center

Phase 1/2
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

M D Anderson Cancer Center

Phase 1
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

The University of Texas M. D. Anderson Cancer Center

Phase 2

San Francisco, California3 trials

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

University of California, San Francisco

Phase 2
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

University of California San Francisco

Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

University of California, San Francisco

Phase 2

Washington D.C., District of Columbia3 trials

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Site 1001

Phase 1/2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Johns Hopkins University: Sibley Memorial Hospital

Phase 2
Evaluating Novel Therapies in ctDNA Positive GI Cancers

Georgetown Lombardi Comprehensive Cancer Center

Phase 3

Phoenix, Arizona2 trials

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

St. Joseph's Hospital and Medical Center

Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Research Site

Phase 3

Beverly Hills, California2 trials

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Beverly Hills Cancer Center

Phase 2
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Tower Cancer Research Foundation

Phase 3

Los Angeles, California2 trials

A Study of VET3-TGI in Patients With Solid Tumors

USC/Norris Comprehensive Cancer Center

Phase 1
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

Keck Medicine of USC Koreatown

Phase 2

New Haven, Connecticut2 trials

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Yale University School of Medicine /ID# 278181

Phase 2
Iadademstat + SBRT With Atezo in ES-SCLC

Yale University

Phase 1

Chicago, Illinois2 trials

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

University of Illinois Cancer Center

Phase 2
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Ann & Robert H. Lurie Children's Hospital of Chicago

Phase 1/2

Bethesda, Maryland2 trials

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

National Institutes of Health Clinical Center

Phase 1
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

National Institutes of Health Clinical Center

Phase 2

Philadelphia, Pennsylvania2 trials

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

University of Pennsylvania Perelman Center for Advanced Medicine

Phase 1
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Abramson Cancer Center of the University of Pennsylvania

Phase 1/2

Nashville, Tennessee2 trials

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Vanderbilt University/Ingram Cancer Center

Phase 1/2
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Vanderbilt University/Ingram Cancer Center

Phase 1/2

Daphne, Alabama1 trial

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Southern Cancer Center, PC

Phase 3

Mobile, Alabama1 trial

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Infirmary Cancer Care

Phase 3

Scottsdale, Arizona1 trial

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Mayo Clinic in Arizona

Phase 2

Tucson, Arizona1 trial

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

ACRC Arizona Clinical Research Center

Phase 3

Fayetteville, Arkansas1 trial

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Highlands Oncology Group

Phase 2/3

Berkeley, California1 trial

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Alta Bates Summit Medical Center-Herrick Campus

Phase 3

Fresno, California1 trial

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

ClinRé 001-022 (Premier Cancer Care and Infusion Center)

Phase 3

La Jolla, California1 trial

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

UC San Diego Moores Cancer Center

Phase 2

Sacramento, California1 trial

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

University of California Davis

Phase 2

Santa Rosa, California1 trial

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Providence Medical Foundation ( Site 0124)

Phase 1/2

Stanford, California1 trial

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

GSK Investigational Site

Phase 1

Lone Tree, Colorado1 trial

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Rocky Mountain Cancer Centers, LLP

Phase 1/2

Gainesville, Florida1 trial

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2

Fairway, Kansas1 trial

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

The University of Kansas Cancer Center (KUCC)

Phase 1/2

Boston, Massachusetts1 trial

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Dana-Farber Cancer Institute

Phase 2

Detroit, Michigan1 trial

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Henry Ford Cancer- Detroit

Phase 2

Rochester, Minnesota1 trial

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic in Rochester

Phase 1/2

St Louis, Missouri1 trial

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

Washington University School of Medicine

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

Buffalo, New York1 trial

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2

New York, New York1 trial

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

Icahn School of Medicine at Mount Sinai

Phase 4

Chapel Hill, North Carolina1 trial

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Lineberger Comprehensive Cancer Center

Phase 1

Winston-Salem, North Carolina1 trial

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Wake Forest Baptist Comprehensive Cancer Center

Phase 2

Columbus, Ohio1 trial

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1

Pittsburgh, Pennsylvania1 trial

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

UPMC Hillman Cancer Center

Phase 2

Germantown, Tennessee1 trial

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Methodist Le Bonheur Healthcare

Phase 1/2

Salt Lake City, Utah1 trial

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Huntsman Cancer Institute/University of Utah

Phase 2

Fairfax, Virginia1 trial

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Inova Schar Cancer Institute - Fair Oaks

Phase 2

Seattle, Washington1 trial

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.